GovChime
Archived

NIDDK in vivo efficacy of Fc-bispecifics study

Overview

Response deadline
9:00 AM EDT
Posted
July 28, 2026
Notice type
Presolicitation
Set-aside
No Set aside used
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH OLAO
Place of performance
Bethesda, Maryland, 20892
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Notice ID
3eadbfedba284bbf8b3e2d14fc4e8f04

Description

As part of the statutorily required functions of the National Institute of Health (NIH), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts and supports a wide range of biomedical research directly through intramural research within NIH laboratories, and externally through grants to universities and other medical research institutions across the country. In addition, NIDDK supports research training for students and scientists at various stages of their careers and a range of education and outreach programs to bring science-based information to patients and their families, health care professionals, and the public.

Within the Laboratory of Bioorganic Chemistry, NIDDK, the Natural Products Chemistry Section (NPCS) requires studies to determine the in vivo anti- human immunodeficiency virus (HIV) and immune-recruiting activity of a novel panel of antibody or Fc-lectin/nanobody conjugates (termed antibody-protein conjugates or APC’s). These studies are being performed with optimized APCs that have been shown to prevent HIV infection in cell-based and vivo studies. The research study is needed to expand a recent pilot study in humanized CD34+ mice (strain NOD- Prkdcem26Cd52Il2rgem26Cd22 /NjuCrl). The protocols used will measure antiviral efficacy of the APCs in both pre-infection and post-infection studies. Viral infection will be measured by polymerase chain reaction (PCR) and flow cytometry of T-cells in infected and control mice. In-life blood collections will be conducted on study dates every 2 weeks (W#):  -1 day (W0), W2, W4, S6 and W8 (end-point) or +1 day (W0), W2, W4, S6 and W8 (end-point). A terminal blood collection will be conducted on day 56 for all mice. Blood processing and serum preparations will be conducted on all samples. Additionally, PCR and flow cytometry will be conducted. A total of six study groups comprising six CD34+ mice per group will be used for testing of five APCs plus vehicle control.

The NPCS carries out research aimed at developing antiviral antibody-protein conjugates with an emphasis on anti-HIV conjugates that offer durable protection. This is a long-term project that has been funded by the Office of AIDS Research. Previous studies tested plasma stability and toxicity (pharmacokinetics) of conjugate mGRFT-Fc(glyc). Favorable results showing protection and recruitment of immune/cytotoxic antiviral responses in APCs containing a glycosylated Fc region indicate the need for expanded testing.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Vishnuvajjala Hanumanth Rao

Documents

Files (1)

  • NoticeofIntentTaconicBiosciences.docx

    75 KBAdded in Presolicitation version 3Posted
    Download

Lifecycle

  1. 3
    Version 3PresolicitationArchivedCurrent

    NIDDK in vivo efficacy of Fc-bispecifics study

    Notice 3eadbfedba284bbf8b3e2d14fc4e8f04 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75N98026Q00898TACONICBIOSCIENCESINC

Archive Date

Aug 7, 2026

Office Address

BETHESDA, MD, 20892